The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Please sign up for SocialPicks site access - it's free!

 Spectrum Pharmaceuticals Inc.  (SPPI) Trade Now »     Rate SPPI  -  Discuss SPPI  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
84.5%
Top:
100.0%
Rate SPPI:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

SPPI: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on SPPI ... Graphic_rating_buy SPPI
0_vader
77%
 +206.79%
in 384 days
(closed on 11/19/09)

SPPI just signed an exclusive collaboration agreement with Allergan, Inc. for the development and comercialization of aqaziuoine.  They will receive $41.5 million at closing and up to $304 million in milestone payments.  When they receive the $41.5 million they should have over $90 million in cash which should be almost $2.85 per share in cash. 

Also, they should be filing a supplemental NDA with the FDA  for their FUSILEV drug for colorectal cancer by the end of October 2008.

By  Darth Vader   (+1.14%  risk: conservative)  10/30/08 Comment


Neutral on SPPI ... SPPI
N/A
 +0.68%
in 5 days
(closed on 10/21/09)
 News of SPPI's  drug delay is digesting.  The stock should begin to increase again soon.  A third  of three  catalysts is up for revue in the coming months and sales from the first should start to help the bottom line.  All shareholders waist 2 in  for the FDA outcome for catalyst 2 in the coming months.
By  robert haag   (-7.04%  risk: conservative)  10/16/09 Comment


Bullish on SPPI ... Graphic_rating_buy SPPI
N/A
 -25.21%
in 72 days
I am a recruiter for them. We are EXPANDING THEIR SALESFORCE FOR FIRST LINE ZEVALIN < AND COLON CANCER SALES OF FUSILEV.
By  drugrecruiter   (-25.21%  risk: conservative)  09/25/09 Comment


RECENT NEWS Graphic_rating_buy SPPI
N/A
 -34.11%
in 87 days
spectrum Pharma tgt raised to $10 at Rodman & Renshaw following FDA approval for the expanded label of Zevalin Rodman & Renshaw raise their SPPI tgt to $10 from $8 following the FDA approval for an expanded label of Zevalin, which treats the previously untreated follicular non-Hodgkin's Lymphoma. With the label expansion, the treatable population expands from 6,000 to potentially 43,000 patients annually, in the firm's opinion.
By  Olof Thomas   (-3.07%  risk: conservative)  09/10/09 Comment


Techical Analysis Graphic_rating_buy SPPI
N/A
 -13.69%
in 1 day
(closed on 09/09/09)
SPPI- a commercial-stage biotechnology company with a primary focus in oncology. Expecting some FDA approval news October 8th that should send this stock flying!
By  Olof Thomas   (-3.07%  risk: conservative)  09/08/09 Comment




From the Blogosphere

Spectrum Pharma: Zevalin Sales Ramp Up

<font>On November 13, Spectrum Pharmaceuticals (SPPI) reported some positive Q3 results. Sales of their non-Hodgkin’s lymphoma (NHL) drug, Zevalin®, which made up more than half of the revenue generated during the quarter, continue to improve significantly.</font>

<><font>Over the past several months, many have argued that a Zevalin comeback was impossible. The drug has been ignored by doctors for several years. For this reason, many argue it’ll never sell today. I will not deny it, changing previously held beliefs and perceptions isn't always easy. Without question, the Zevalin turnaroun...
By  trackseekingalpha   (-13.40%  risk: aggressive)  11/22/09 Comment


Spectrum Pharma: CMS Rules in Favor of Zevalin

Spectrum Pharmaceuticals (SPPI) just announced that the Centers for Medicare and Medicade Services (CMS) ruled in favor of the company's radio-immunotherapy Zevalin®. Zevalin is now approved as a first-line treatment for patients with non-Hodgkin's lymphoma (NHL).

This is good news for SPPI as Zevalin will now be reimbursed at an average sales price (ASP) of most other cancer drugs. As I understand it, this ruling means that Zevain should now be reimbursed at a price +5% to +6% from its current price. It should be noted that the new price will be effective as of January 1, 2010.
By  trackseekingalpha   (-13.40%  risk: aggressive)  11/03/09 Comment


Spectrum Pharma: Zevalin Has Blockbuster Potential

A number of positive peer-reviews evaluating Spectrum Pharmaceuticals (SPPI) radio-immunotherapy (RIT), Zevalin® were published this month. The conclusions drawn in these reviews were made from unbiased medical professionals, and indicate that the prospects for Zevalin may be greater than I originally estimated back on <font>June 12</font>.

Based on the feedback received from a doctor whose opinion I value, I now believe Zevalin has blockbuster potential. In general, blockbuster drugs typically generate annual revenue of $1 billion or greater.
By  trackseekingalpha   (-13.40%  risk: aggressive)  10/25/09 Comment


Spectrum Pharma (SPPI) drops on cancer drug setback

Filed under: Major movement, Bad news, Options, Technical Analysis

SPPI logoSpectrum Pharmaceutical (NASDAQ: SPPI - option chain) stock is trading lower today after the company received a Complete Response letter from the FDA regarding FUSILEV, its treatment for advanced metastatic colorectal cancer. The FDA said the company did not demonstrate that FUSILEV is non-inferior to leucovorin in its supplemental New Drug Application. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SPPI.

This morning, SPPI opened at $4.98....
By  Brent Archer   (-58.07%  risk: moderate)  10/09/09 Comment


Spectrum Pharmaceuticals: Undervalued and (Now) Oversold

<font>ROUND ONE</font>

<font>During the last pullback, Spectrum Pharmaceuticals (SPPI)</font><font> began to sell-off on June 30 after shares of the company had reached the first new multi-year high since July 2007. On June 30, SPPI topped at $8.15 and closed at $7.65.</font>
By  trackseekingalpha   (-13.40%  risk: aggressive)  09/24/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
PG The Procter & Gamble Company
CSCO Cisco Systems Inc
POT Potash Corp. of Saskatchewan Inc.
KO The CocaCola Company
BIDU Baiducom Inc ADS
GE General Electric Company

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on SPPI

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Spectrum Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch